Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report). The associated price target remains the same with $44.00.
Rami Katkhuda’s rating is based on the promising results from Mineralys Therapeutics, Inc.’s recent clinical trials, particularly the Advance-HTN and Launch-HTN studies. The data revealed that lorundrostat, the company’s lead therapeutic candidate, demonstrated significant reductions in systolic blood pressure, with a 15.4 mmHg absolute and 7.9 mmHg placebo-adjusted reduction, which impressed key opinion leaders (KOLs) at the conference.
Moreover, the treatment showed a favorable safety profile with lower-than-expected rates of hyperkalemia, a common concern in similar therapies. The consistency of lorundrostat’s efficacy across various patient subgroups, including different sexes, races, and BMI categories, further supports its potential as a versatile treatment option. These factors, combined with the belief that the drug class could be used in earlier lines of treatment, underpin Katkhuda’s Buy rating for the stock.
Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Viridian Therapeutics, and VYNE Therapeutics. According to TipRanks, Katkhuda has an average return of 18.0% and a 38.36% success rate on recommended stocks.
In another report released on March 13, Bank of America Securities also maintained a Buy rating on the stock with a $38.00 price target.